Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21191726 | 0.96 | HTR2A (0.34) | HTR2ACYP1A2 | |
| SCHEMBL18459246 | 0.95 | HTR2A (0.32) | HTR2A | |
| SCHEMBL22023694 | 0.93 | HTR2A (0.33) | HTR2ACYP1A2 | |
| SCHEMBL22024127 | 0.93 | HTR2A (0.33) | HTR2A | |
| SCHEMBL24736818 | 0.92 | CCR2 (0.34) | HTR2A | |
| SCHEMBL26317203 | 0.92 | CCR2 (0.34) | HTR2A | |
| SCHEMBL22141963 | 0.90 | CCR2 (0.35) | HTR2A | |
| SCHEMBL22142074 | 0.90 | CCR2 (0.35) | HTR2A | |
| SCHEMBL27293416 | 0.86 | SSTR4 (0.34) | CYP1A2 | |
| SCHEMBL25733300 | 0.84 | GNAO1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295113-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | HTR2A 1815/4885CYP1A2 2072/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | HTR2A 4389/4885CYP1A2 222/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | HTR2A 4389/4885CYP1A2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.